-
Novel serum biomarkers to differentiate cholangiocarcinoma from benign biliary tract diseases using a proteomic approach
- Back
Document Title
Novel serum biomarkers to differentiate cholangiocarcinoma from benign biliary tract diseases using a proteomic approach
Author
Janvilisri T., Leelawat K., Roytrakul S., Paemanee A., Tohtong R.
Name from Authors Collection
Affiliations
Department of Biochemistry, Faculty of Science, Mahidol University, 272 Rama VI Road, Phayathai, Rajdhevi, Bangkok, 10400, Thailand; Department of Surgery, Rajavithi Hospital, Bangkok, 10400, Thailand; Proteomics Research Laboratory, Genome Institute, National Center for Genetic Engineering and Biotechnology, NSTDA, Pathumthani, 12120, Thailand
Type
Article
Source Title
Disease Markers
ISSN
02780240
Year
2015
Volume
2015
Open Access
Gold, Green
Publisher
Hindawi Limited
DOI
10.1155/2015/105358
Abstract
Background and Aim: Cholangiocarcinoma (CCA) is the most frequent biliary malignancy, which poses high mortality rate due to lack of early detection.Hence, most CCAcases are present at the advanced to late stages with local or distant metastasis at the time of diagnosis. Currently available tumor markers including CA19-9 and CEA are inefficient and of limited usage due to low sensitivity and specificity.Here, we attempt to identify serum tumormarkers for CCA that can effectively distinguish CCA frombenign biliary tract diseases (BBTDs). Methods. Serum samples from 19 CCA patients and 17 BBTDs were separated by SDS-PAGE followed with LC-MS/MS and were subjected to statistical analysis and cross-validation to identify proteins whose abundance was significantly elevated or suppressed in CCAsamples compared to BBTDs. Results. In addition to identifying several proteins previously known to be differentially expressed in CCA and BBTDs, we also discovered a number of molecules that were previously not associated with CCA. These included FAM19A5, MAGED4B, KIAA0321, RBAK, and UPF3B. Conclusions. Novel serum biomarkers to distinguish CCA from BBTDs were identified using a proteomic approach. Further validation of these proteins has the potential to provide a biomarker for differentiating CCA from BBTDs. © 2015 Tavan Janvilisri et al.
Industrial Classification
Knowledge Taxonomy Level 1
Knowledge Taxonomy Level 2
Knowledge Taxonomy Level 3
License
CC BY
Rights
Author
Publication Source
Scopus